Abstract: Treatment strategies for oral cancer are still primarily based on tumor-node-metastasis classification. A variety of prognostic biological markers correlated to survival have been described over the years, but very few of these have been tested for prognostic accuracy. The advent of genome-wide screening methods such as comparative genomic hybridization, Microarray, microsatellites and SNPs have opened up new possibilities to catalogue chromosomal aberrations, point mutation for disease diagnosis as well as therapeutic validation. Aberration of the Tylosis Oesophageal Cancer (TOC ) gene mapped to chromosome 17q25 has been recognized as a genetic marker for the development of Oesophageal, Breast and Ovarian cancer. Material & Methods: A total of 26 Microsatellite markers at 17q25 were examined in 150 OSCC patients treated with cisplatin and capecitabine to establish genetic marker for early detection and therapeutic validation. A total of 150 primary tumor tissues, and corresponding blood samples from patients attending the Chhatrapati Shahuji Mahraj Medical University Lucknow from 2003 to 2006, were collected. The tissue samples were obtained, either at the time of investigative biopsy or during the time of the surgical resection of the lesions. Results: Overall incidence of LOH/MSI was 40%±20.84 with the frequency of LOH and MSI of individual markers ranged from 12-93%. LOH was relatively more frequently detected at five loci, namely D17S1817 (57.33%), D17S1864 (81.33%), D17S1603 (68.66%), D17S1602 (93.33%), D17S929 (64%). Low incidence of LOH and MSI was observed in D17S2238 (20.7%) and D17S926 (12.66%) and D17S2101 (18.7%). Conclusion: To our knowledge, this is the first report suggesting an association between allelic loss at D9S1602 & D17S1864 on TOC loci and recurrence in OSCC from India in patients treated with Cisplatin & Capecitabine.

Abstract: Treatment strategies for oral cancer are still primarily based on tumor-node-metastasis classification. A variety of prognostic biological markers correlated to survival have been described over the years, but very few of these have been tested for prognostic accuracy. The advent of genome-wide screening methods such as comparative genomic hybridization, Microarray, microsatellites and SNPs have opened up new possibilities to catalogue chromosomal aberrations, point mutation for disease diagnosis as well as therapeutic validation. Aberration of the Tylosis Oesophageal Cancer (TOC ) gene mapped to chromosome 17q25 has been recognized as a genetic marker for the development of Oesophageal, Breast and Ovarian cancer. Material & Methods: A total of 26 Microsatellite markers at 17q25 were examined in 150 OSCC patients treated with cisplatin and capecitabine to establish genetic marker for early detection and therapeutic validation. A total of 150 primary tumor tissues, and corresponding blood samples from patients attending the Chhatrapati Shahuji Mahraj Medical University Lucknow from 2003 to 2006, were collected. The tissue samples were obtained, either at the time of investigative biopsy or during the time of the surgical resection of the lesions. Results: Overall incidence of LOH/MSI was 40%±20.84 with the frequency of LOH and MSI of individual markers ranged from 12-93%. LOH was relatively more frequently detected at five loci, namely D17S1817 (57.33%), D17S1864 (81.33%), D17S1603 (68.66%), D17S1602 (93.33%), D17S929 (64%). Low incidence of LOH and MSI was observed in D17S2238 (20.7%) and D17S926 (12.66%) and D17S2101 (18.7%). Conclusion: To our knowledge, this is the first report suggesting an association between allelic loss at D9S1602 & D17S1864 on TOC loci and recurrence in OSCC from India in patients treated with Cisplatin & Capecitabine.